Re: A lesson on futility analyses from the CETP inhibitors
in response to
by
posted on
May 11, 2017 08:01AM
Hi Bear,
I would think that none of those CETP inhibitor trial had anything close to the results of the pos Hoc analysis RVX 208 had from the ASSURE trial. With the criteria low HDL and diabetic in the betonmace trial and with now 3 DSMB safety clearances our chances for succeding might very good or better than the CETP inhibitors